Burkitt’s lymphoma (BL) is one of the high-grade lymphomas, characterized by a rapid growth. They are usually treated with intensive chemotherapy regimens, being normally chemo-sensitive, but at the expense of high toxicity secondary to treatment. Additionally, the compromise of the central nervous system (CNS) implies a major risk as well as greater toxicity, taking into account a worse clinical prognosis with a requirement of more intensive schemes to achieve control of the disease. This implies doubts in the management of older patients with BL with CNS compromise, in whom toxicity is a limitation to these therapies, and there are no other alternatives that offer better benefit in terms of less frequent or severe adverse events, with similar outcomes in terms of progression-free survival (PFS) or overall survival (OS). Therefore, clarifying cases such as the one we report below allows us to provide a therapeutic alternative for older or unfit patients, in whom the intention of treatment should be to seek a good tumor response, but without ignoring the potential toxicity of chemotherapy.